Abstract:Background Continuous glucose monitors (CGM) provide detailed information regarding glycemic control in pregnant patients with type 1 diabetes (T1D). Little data have been published examining the association between CGM parameters and perinatal outcomes among gravidas with T1D using CGM. Objective To examine the association between perinatal outcomes and time-in-range (TIR) as assessed by CGM used in pregnant individuals with T1D. We hypothesized that higher TIR would be associated with lower risk of adverse perinatal outcomes. Study design This multicenter retrospective cohort study included all gravidas with T1D using CGM who delivered in 2020-2022 at 5 University of California sites. Only those with CGM target range set to 70-140 mg/dL (±10 mg/dL) were included. TIR (%) was recorded at 12, 16, 20, 24, 28, and 32 weeks. The primary maternal and neonatal outcomes were preeclampsia and large for gestational age (LGA), defined as birthweight (BW) ≥ 95th percentile. Kruskal-Wallis tests were used to compared median TIR in those with and without the primary outcomes. Log-binomial regression was used to obtain risk ratios, with adjustment for microvascular disease and years with T1D. Results A total of 91 patients were included. Most used an insulin pump (81%) and did not have diabetic microvascular disease (72%). Median time since diagnosis of T1D was 16 years, and median periconception A1c was 6.7%. Compared to those with preeclampsia, normotensive gravidas had significantly higher TIR at nearly every time point. A similar pattern was seen for those with normal BW infants compared to LGA infants. On adjusted analyses, every 5-unit increase in TIR at 12 weeks was associated with a 45% and 46% reduction in the risk of preeclampsia and LGA, respectively (ARR 0.55, 95% CI 0.30-0.99 for preeclampsia; ARR 0.54, 95% CI 0.29-0.99 for LGA). Conclusions Higher TIR is associated with lower risk of preeclampsia and LGA. This association is seen early in gestation, when each 5-unit increase in TIR is associated with ∼50% reduction in the risk of these complications. These findings can be used to counsel patients regarding risk of pregnancy complications at specific TIR values and to encourage patients that even small improvements in TIR can have significant impact on pregnancy outcomes. Larger studies are needed to further explore these findings and to identify optimal TIR to reduce perinatal complication rates.

'We're taught green is good': Perspectives on time in range and time in tight range from youth with type 1 diabetes, and parents of youth with type 1 diabetes

Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes

Time In Tight Range in children and adolescents with type 1 diabetes: A cross‐sectional observational single centre study evaluating efficacy of new advanced technologies

Assessing the feasibility of time in tight range (TITR) targets with advanced hybrid closed loop (AHCL) use in children and adolescents: A single‐centre real‐world study

Situational Awareness and Proactive Engagement Predict Higher Time in Range in Adolescents and Young Adults Using Hybrid Closed-Loop

The interdependence of targets for continuous glucose monitoring outcomes in type 1 diabetes with automated insulin delivery

Time spent outside of target glucose range for young children with type 1 diabetes: a continuous glucose monitor study

Exploring the Continuous Glucose Monitoring in Pediatric Diabetes: Current Practices, Innovative Metrics, and Future Implications

Psychosocial outcomes in a diverse sample of youth and their families who initiated continuous glucose monitoring within the first year of type 1 diabetes diagnosis

Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1-year real-world assessment

Author Response for "time in Tight Range: A Key Metric for Optimal Glucose Control in the Era of Advanced Diabetes Technologies and Therapeutics"

Time in tight range: A key metric for optimal glucose control in the era of advanced diabetes technologies and therapeutics

Glucose metrics improvement in youths with type 1 diabetes using the Ambulatory Glucose Profile report: A real-world study

Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems

Continuous glucose monitoring in pregnancies with type 1 diabetes: small increases in time-in-range improve maternal and perinatal outcomes

Association between continuous glucose monitoring metrics and clinical outcomes in adults with type 1 diabetes in a real-world setting

Twelve-month psychosocial outcomes of continuous glucose monitoring with behavioural support in parents of young children with type 1 diabetes

Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Perspective of Continuous Glucose Monitoring-Based Interventions at the Various Stages of Type 2 Diabetes

A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes